TY - JOUR
T1 - A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome
AU - Goodkin, Karl
AU - Gullion, Christina M.
AU - Agras, W. Stewart
N1 - Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 1990/8
Y1 - 1990/8
N2 - A 6-week placebo-controlled trial evaluated the efficacy of trazodone hydrochloride for the relief of chronic low back pain. Forty-two subjects (22 trazodone, 20 placebo) with a 20.3-year average history of back pain were titrated to an average dose of trazodone 201 mg or placebo 238 mg and evaluated daily on a Visual Analogue Scale of pain intensity, at 2-week intervals on an observer rating of pain behavior while walling, and before and after the trial on the Beck Depression Inventory, the Sickness Impact Profile, and a solid state microcomputer (Vitalog) that measured physical activity. Trazodone blood levels and urine toxicology screens were also obtained. There were no significant differences between groups in treatment effect. The results of this study require confirmation by longer trials with larger, less chronic, more homogeneous samples at higher doses with follow-up assessments.
AB - A 6-week placebo-controlled trial evaluated the efficacy of trazodone hydrochloride for the relief of chronic low back pain. Forty-two subjects (22 trazodone, 20 placebo) with a 20.3-year average history of back pain were titrated to an average dose of trazodone 201 mg or placebo 238 mg and evaluated daily on a Visual Analogue Scale of pain intensity, at 2-week intervals on an observer rating of pain behavior while walling, and before and after the trial on the Beck Depression Inventory, the Sickness Impact Profile, and a solid state microcomputer (Vitalog) that measured physical activity. Trazodone blood levels and urine toxicology screens were also obtained. There were no significant differences between groups in treatment effect. The results of this study require confirmation by longer trials with larger, less chronic, more homogeneous samples at higher doses with follow-up assessments.
UR - http://www.scopus.com/inward/record.url?scp=0025024966&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025024966&partnerID=8YFLogxK
M3 - Article
C2 - 2149565
AN - SCOPUS:0025024966
VL - 10
SP - 269
EP - 278
JO - Journal of Clinical Psychopharmacology
JF - Journal of Clinical Psychopharmacology
SN - 0271-0749
IS - 4
ER -